A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

Phase 2 Terminated 25 enrolled Aristea Therapeutics, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Hidradenitis Suppurativa

Timeline

Start: 2022-07-18
Primary completion: 2023-02-28
Completion: 2023-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VIMNERIXIN	Small molecule	400 mg	Oral

A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

Summary

Timeline

Drugs

Indications